- Home
- RTC vs CHRS Comparison
RTC vs CHRS Comparison
Compare RTC & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RTC
- CHRS
- Stock Information
- Founded
- RTC 2003
- CHRS 2010
- Country
- RTC China
- CHRS United States
- Employees
- RTC N/A
- CHRS N/A
- Industry
- RTC Specialty Chemicals
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RTC Industrials
- CHRS Health Care
- Exchange
- RTC Nasdaq
- CHRS Nasdaq
- Market Cap
- RTC 23.3M
- CHRS 191.3M
- IPO Year
- RTC N/A
- CHRS 2014
- Fundamental
- Price
- RTC $0.67
- CHRS $1.16
- Analyst Decision
- RTC
- CHRS Strong Buy
- Analyst Count
- RTC 0
- CHRS 4
- Target Price
- RTC N/A
- CHRS $5.38
- AVG Volume (30 Days)
- RTC 487.0K
- CHRS 2.4M
- Earning Date
- RTC 03-13-2025
- CHRS 03-12-2025
- Dividend Yield
- RTC N/A
- CHRS N/A
- EPS Growth
- RTC N/A
- CHRS N/A
- EPS
- RTC N/A
- CHRS N/A
- Revenue
- RTC $59,794,661.00
- CHRS $304,340,000.00
- Revenue This Year
- RTC N/A
- CHRS $2.47
- Revenue Next Year
- RTC N/A
- CHRS N/A
- P/E Ratio
- RTC N/A
- CHRS N/A
- Revenue Growth
- RTC N/A
- CHRS 44.19
- 52 Week Low
- RTC $0.65
- CHRS $0.66
- 52 Week High
- RTC $9.69
- CHRS $2.87
- Technical
- Relative Strength Index (RSI)
- RTC 12.37
- CHRS 38.01
- Support Level
- RTC $0.72
- CHRS $1.03
- Resistance Level
- RTC $1.64
- CHRS $1.39
- Average True Range (ATR)
- RTC 0.27
- CHRS 0.14
- MACD
- RTC 0.06
- CHRS -0.03
- Stochastic Oscillator
- RTC 2.91
- CHRS 14.04
About RTC Baijiayun Group Ltd.
Baijiayun Group Ltd is a ToB video cloud technology service provider that solves various pain points and needs in the field of video technology applications for enterprises. The group supplies energy for the digital development of enterprises through audio and video technology. The firm provides video technology solutions to enterprises and government agencies in various fields such as automobiles, finance, education, and medical care. Baijiayun has created three categories of product services namely video SaaS/PaaS business, video cloud products and software, and video system solutions. It has set up multiple R&D centers, branches, and offices across the country, enabling video technology to create industrial value and promote the development of the real economy.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.